<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04087941</url>
  </required_header>
  <id_info>
    <org_study_id>HOPES</org_study_id>
    <nct_id>NCT04087941</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial</brief_title>
  <official_title>Hepatocyte Growth Factor for Opioid-Dependent Pain: Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy (The HOPES Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, randomized, placebo-controlled, single-center, 12-month phase 2 study
      designed to assess the safety and efficacy of VM202 as a replacement for opioid analgesics in
      opioid-tolerant subjects with painful diabetic peripheral neuropathy (DPN).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 24-hour Morphine Milligram Equivalents (MME)</measure>
    <time_frame>baseline week to week prior to Day 180</time_frame>
    <description>The percent change in 24-hour MME use from baseline week to the week prior to Day 180 obtained from the Daily Pain and Sleep Interference Diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid use - mean dose</measure>
    <time_frame>Day 90, Day 180, Day 270, Day 365</time_frame>
    <description>mean dose of opioid reported in 24-hour MME at each timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid use - percent change from baseline</measure>
    <time_frame>Day 90, Day 180, Day 270, Day 365</time_frame>
    <description>percent change from baseline in 24-hour MME during the week prior to each timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid use - percent of subjects who are dose-reduced/opioid free</measure>
    <time_frame>Day 90, Day 180, Day 270, Day 365</time_frame>
    <description>percent of subjects whose daily opioid consumption is reduced by 50% and 100% (opioid-free) at each timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid-Related AE - Cognition</measure>
    <time_frame>Day 90, Day 180, Day 270, Day 365</time_frame>
    <description>Cognition as measured with Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) assessed at each timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid-Related AE - Bowel Function</measure>
    <time_frame>Day 90, Day 180, Day 270, Day 365</time_frame>
    <description>Bowel Function Inventory-revised (BFI-R) assessed at each timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid-Related AE - Numerical Opioid Side Effect (NOSE)</measure>
    <time_frame>Day 90, Day 180, Day 270, Day 365</time_frame>
    <description>NOSE assessed at each timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy- Change in Average Pain Intensity</measure>
    <time_frame>baseline week to week prior to Day 180</time_frame>
    <description>the change in average pain intensity from baseline week to the week prior to Day 180 obtained from the daily eDiaries</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Painful Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-202</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VM-202</intervention_name>
    <description>VM202 is a DNA plasmid that contains novel genomic cDNA hybrid human hepatocyte growth factor (HGF) coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>VM-202</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years to 75 years;

          2. Documented history of Type I or II diabetes with current treatment
             control(glycosylated hemoglobin A1c of ≤ 10.0% at Screening) and currently on oral
             medication and / or insulin;

          3. Taking 60 to 200 mg morphine milligram equivalents (MME)/day for painful DPN at study
             entry and must be on stable regimen starting at Day -21; percent of overall
             requirement as immediate release must be ≥ 30%;

          4. No significant changes anticipated in diabetes medication regimen;

          5. No new symptoms associated with diabetes within the last 3 months prior to study
             entry;

          6. Diagnosis of painful diabetic peripheral neuropathy in both lower extremities;

          7. Global pain intensity [Numerical rating scale, average NRS] score over the week prior
             to initial Screening visit must be ≥ 4 and ≤ 9 (0 = no pain - 10 = worst pain
             imaginable);

          8. Symptoms from the Brief Pain Neuropathy Screening (BPNS) is ≤ 5 point difference
             between legs at Initial Screening;

          9. The physical examination component of the Michigan Neuropathy Screening Instrument
             Score (MNSI) is ≥ 3 at Initial Screening;

         10. Subjects on gabapentin (Neurontin), pregabalin (Lyrica), or duloxetine (Cymbalta) for
             painful DPN at study entry must be on a stable regimen of these treatments for at
             least 7 days prior to start of oral placebo run-in; and

         11. If female of childbearing potential, negative urine pregnancy test at screening and
             using acceptable method of birth control during the study.

        Exclusion Criteria:

          1. Small fiber polyneuropathy caused by condition other than diabetes;

          2. Additional pain syndrome of overall greater intensity than that of DPN that, in the
             opinion of the investigator, would prevent assessment of DPN;

          3. Progressive or degenerative neurological disorder;

          4. Myopathy;

          5. Inflammatory disorder of the blood vessels (inflammatory angiopathy, such as Buerger's
             disease);

          6. Active infection, in the opinion of the investigator;

          7. Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis), in the
             opinion of the investigator;

          8. Positive HIV or HTLV at Screening;

          9. Active Hepatitis B or C as determined by Hepatitis B core antibody (HBcAb; IgG and
             IgM), antibody to Hepatitis B surface antigen (HBsAb), Hepatitis B surface antigen
             (HBsAg) and Hepatitis C antibodies (Anti-HCV) at Screening;

         10. Subjects with known immunosuppression or currently receiving immunosuppressive drugs,
             chemotherapy or radiation therapy;

         11. Stroke or myocardial infarction within last 3 months;

         12. Specific laboratory values at Screening including: Hemoglobin &lt; 8.0 g/dL, WBC &lt; 3,000
             cells per microliter, platelet count &lt;75,000/mm3, Creatinine &gt; 2.0 mg/dL; AST and/or
             ALT &gt; 3 times the upper limit of normal or any other clinically significant lab
             abnormality which in the opinion of the investigator should be exclusionary;

         13. Proliferative retinopathy within 5 years of signing consent or any ophthalmological
             condition which, in the opinion of the investigator, should be exclusionary; any
             condition that precludes standard ophthalmologic examination;

         14. Uncontrolled hypertension defined as sustained systolic blood pressure (SBP) &gt; 200
             mmHg or diastolic BP (DBP) &gt; 110 mmHg at Screening;

         15. Subjects with a recent history (&lt; 5 years) of or new screening finding of malignant
             neoplasm except basal cell carcinoma or squamous cell carcinoma of the skin (if
             excised and no evidence of recurrence for one year); subjects with family history of
             colon cancer in any first degree relative are excluded unless they have undergone a
             colonoscopy in the last 12 months with negative findings;

         16. Use of the following drugs / therapeutics is PROHIBITED past Day -14:

               -  skeletal muscle relaxants, benzodiazepines (except for stable bedtime dose),

               -  capsaicin, local anesthetic creams and patches, isosorbide dinitrate (ISDN)
                  spray,

               -  transcutaneous electrical nerve stimulation (TENS), acupuncture

         17. If not using gabapentin (Neurontin), pregabalin (Lyrica), duloxetine (Cymbalta), any
             antidepressants (e.g., amitriptyline and venlafaxine), any other antiepileptics (e.g.,
             valproic acid, carbamazepine, or vigabatrin), subjects must agree not to start these
             drugs until after Day 180. Subjects on these medications on day of informed consent
             must maintain a stable dose starting at Day -21 until Day 180; any changes in
             analgesic regimen after Day 180 are at the discretion of the investigator;

         18. Use of certain COX-1/COX-2 inhibitor drug(s), steroids (except inhaled, ocular, or
             intra-articular steroids), and anti-Vascular Endothelial Growth Factor (VEGF) agents;
             subjects may be enrolled if willing/able to undergo medication wash-out prior to the
             first dosing and to refrain from taking these drugs for the duration of the study;

         19. Major psychiatric disorder within last 6 months that would interfere with study
             participation;

         20. Body mass index (BMI) &gt; 45 kg/m2 at Screening;

         21. Any prior or lower extremity amputation due to diabetic complications;

         22. History of illicit drug or alcohol abuse / dependence in the past 2 years, including
             but not limited to, cocaine, amphetamines, non-prescribed opioids, and non-prescribed
             benzodiazepines);

         23. Use of an investigational drug or treatment in past 6 months; and

         24. Unable or unwilling to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine N. Sang, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine N. Sang, MD, MPH</last_name>
    <phone>617-525-7246</phone>
    <email>csang@bwh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Translational Pain Research, Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>September 12, 2019</last_update_submitted>
  <last_update_submitted_qc>September 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Christine N. Sang, MD, MPH</investigator_full_name>
    <investigator_title>Director, Translational Pain Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

